The study demonstrated that in treatment-naive metastatic NSCLC cancer patients, there was a significant gain in overall survival with the association of pembrolizumab with chemotherapy, and this result was seen in all categories of PDL-1 expression positivity. The gene discussed is CD274; the disease is non-small cell lung carcinoma.